- Home
- AVD vs STTK Comparison
AVD vs STTK Comparison
Compare AVD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- STTK
- Stock Information
- Founded
- AVD 1969
- STTK 2016
- Country
- AVD United States
- STTK United States
- Employees
- AVD N/A
- STTK N/A
- Industry
- AVD Agricultural Chemicals
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- AVD Industrials
- STTK Health Care
- Exchange
- AVD Nasdaq
- STTK Nasdaq
- Market Cap
- AVD 104.4M
- STTK 37.6M
- IPO Year
- AVD N/A
- STTK 2020
- Fundamental
- Price
- AVD $3.71
- STTK $0.79
- Analyst Decision
- AVD Strong Buy
- STTK Hold
- Analyst Count
- AVD 1
- STTK 4
- Target Price
- AVD $12.00
- STTK $3.00
- AVG Volume (30 Days)
- AVD 240.0K
- STTK 470.6K
- Earning Date
- AVD 08-07-2025
- STTK 07-31-2025
- Dividend Yield
- AVD N/A
- STTK N/A
- EPS Growth
- AVD N/A
- STTK N/A
- EPS
- AVD N/A
- STTK N/A
- Revenue
- AVD $527,962,999.00
- STTK $4,606,000.00
- Revenue This Year
- AVD N/A
- STTK N/A
- Revenue Next Year
- AVD $3.54
- STTK N/A
- P/E Ratio
- AVD N/A
- STTK N/A
- Revenue Growth
- AVD N/A
- STTK 69.65
- 52 Week Low
- AVD $3.28
- STTK $0.69
- 52 Week High
- AVD $9.84
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- AVD 41.28
- STTK 39.92
- Support Level
- AVD $3.90
- STTK $0.75
- Resistance Level
- AVD $4.25
- STTK $0.85
- Average True Range (ATR)
- AVD 0.22
- STTK 0.08
- MACD
- AVD -0.01
- STTK -0.01
- Stochastic Oscillator
- AVD 30.97
- STTK 10.56
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.